Home > Cardiology > HFA 2022 > Dapagliflozin performs consistently across LVEF in HF

Dapagliflozin performs consistently across LVEF in HF

Presented By
Dr Mikhail Kosiborod, St. Luke’s Hospital, USA
Conference
HFA 2022
Trial
DEFINE-HF; PRESERVED-HF
Dapagliflozin was associated with the improvement of symptoms and physical limitations of patients with heart failure (HF) across the entire range of left ventricular ejection fractions (LVEFs). With this finding, the current pooled analysis of the DEFINE-HF  and PRESERVED-HF trials supports the use of dapagliflozin in patients with HF, irrespective of LVEF. “Whether sodium-glucose cotransporter-2 (SGLT2) inhibitors consistently improve the symptoms and physical limitations across the entire range of LVEF in patients with HF is not well established,” explained Dr Mikhail Kosiborod (St. Luke’s Hospital, MO, USA) [1]. Therefore, a pooled analysis of the DEFINE-HF trial (NCT02653482), including 263 patients with LVEF ≤40%, and the PRESERVED-HF trial (NCT03030235), includin...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on